Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19

Author： Furuta Takahisa  

Publisher： Adis International

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.16, Iss.4, 2012-08, pp. : 223-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID‐Induced Gastropathy

By  

PAIN MEDICINE, Vol. 16, Iss. 5, 2015-05 ,pp. : 866-869

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gastroesophageal Reflux Disease

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 46, Iss. 12, 1998-12 ,pp. : 1558-1565

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 349-349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 2, 2015-08 ,pp. : 267-275

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 3, 2018-03 ,pp. : 510-519

John Wiley & Sons Inc

Access to resources Recommend Favorite